Bcl-2-like 14 antibody
Principal name
Bcl-2-like 14 antibody
Alternative names for Bcl-2-like 14 antibody
Bcl-G, Bcl2-L-14, BCLG, BCL2L14, Apoptosis facilitator Bcl-2-like protein 14
Ncbi ID
9606, NP_110393.1, NM_030766, NP_620048, NP_620049, NP_110393, NP_080054.1, NM_025778, NM_001024338, NM_138723, NM_138724, NM_138722
Available reactivities
Available hosts
Available applications
Enzyme Immunoassay (E), Western blot / Immunoblot (WB), ELISA (detection) (E(detection)), Immunocytochemistry/Immunofluorescence (ICC/IF), Paraffin Sections (P), EPair for Elisa (EPair)
Background of Bcl-2-like 14 antibody
Members in the Bcl-2 family are critical regulators of apoptosis by either inhibiting or promoting cell death. Bcl-2 homology 3 (BH3) domain is a potent death domain (reviewed in 1 and 2). BH3 domain containing pro-apoptotic proteins, including Bad, Bax, Bid, Bik, and Hrk, form a growing subclass of the Bcl-2 family. A novel BH3 domain containing protein was recently identified and designated Bcl-G (3). The mRNA of Bcl-G encodes 2 isoforms, Bcl-GL, which is widely expressed in multiple tissues, and Bcl-GS, which is only found in testis. The Bcl-GS protein is predominantly localized to cytoplasmic organelles whereas Bcl-GL was distributed throughout the cytosol. Overexpression of either protein induced apoptosis, although Bcl-GS was far more potent than Bcl-GS. Apoptosis induction was dependent on the BH3 domain and could be suppressed by co-expression with the anti-apoptotic Bcl-XL protein (3).










Primary Antibodies
Catalog No. | Host | Iso. | Clone | Pres. | React. | Applications | |
---|---|---|---|---|---|---|---|
TA306135 | Bcl-2-like 14 (C-term) antibody |
||||||
Rabbit Polyclonal Bcl-G Antibody | |||||||
![]() |
Rabbit | Purified | Hu, Ms, Rt | E, P, WB |
0.1 mg /
€371.00
|
||
OriGene Technologies, Inc. | |||||||
![]() |
|||||||
TA315784 | Bcl-2-like 14 antibody |
||||||
Rabbit polyclonal anti-BCL2L14 antibody | |||||||
![]() |
Rabbit | IgG | Purified | Hu, Ms | E, WB |
0.1 ml /
€335.00
|
|
OriGene Technologies, Inc. | |||||||
TA349545 | Bcl-2-like 14 antibody |
||||||
Rabbit Polyclonal Anti-BCL2L14 Antibody | |||||||
![]() |
Rabbit | IgG | Purified | Hu | E, P |
0.1 ml /
€335.00
|
|
OriGene Technologies, Inc. | |||||||
![]() |
|||||||
AP07282PU-N | Bcl-2-like 14 (C-term) antibody |
||||||
![]() |
Rabbit | Purified | Hu, Ms, Rt | P, WB |
50 µg /
€380.00
|
||
Acris Antibodies GmbH | |||||||
![]() |
|||||||
AP11296PU-N | Bcl-2-like 14 (BH3 Domain) antibody |
||||||
![]() |
Rabbit | Ig | Purified | Hu, Ms | P, WB |
0.4 ml /
€370.00
|
|
Acris Antibodies GmbH | |||||||
![]() |
CRISPR
Catalog No. | Species | Donor Vector | |
---|---|---|---|
KN206404 | BCL2L14 - human gene knockout kit via CRISPR |
||
![]() |
Human | GFP-Puro |
1 kit /
€1,290.00
|
OriGene Technologies, Inc. | |||
KN206404BN | BCL2L14 - human gene knockout kit via CRISPR |
||
![]() |
Human | mBFP-Neo |
1 kit /
€1,290.00
|
OriGene Technologies, Inc. | |||
KN206404LP | BCL2L14 - human gene knockout kit via CRISPR |
||
![]() |
Human | Luciferase-Puro |
1 kit /
€1,290.00
|
OriGene Technologies, Inc. | |||
KN206404RB | BCL2L14 - human gene knockout kit via CRISPR |
||
![]() |
Human | RFP-BSD |
1 kit /
€1,290.00
|
OriGene Technologies, Inc. | |||
KN302106 | Bcl2l14 - mouse gene knockout kit via CRISPR |
||
![]() |
Mouse | GFP-Puro |
1 kit /
€1,290.00
|
OriGene Technologies, Inc. | |||
KN302106BN | Bcl2l14 - mouse gene knockout kit via CRISPR |
||
![]() |
Mouse | mBFP-Neo |
1 kit /
€1,290.00
|
OriGene Technologies, Inc. | |||
KN302106LP | Bcl2l14 - mouse gene knockout kit via CRISPR |
||
![]() |
Mouse | Luciferase-Puro |
1 kit /
€1,290.00
|
OriGene Technologies, Inc. | |||
KN302106RB | Bcl2l14 - mouse gene knockout kit via CRISPR |
||
![]() |
Mouse | RFP-BSD |
1 kit /
€1,290.00
|
OriGene Technologies, Inc. |
Proteins & Growth Factors
Catalog No. | Species | Pres. | Purity | Source | |
---|---|---|---|---|---|
TP306404 | Bcl-2-like 14 (transcript variant 1) |
||||
Recombinant protein of human BCL2-like 14 (apoptosis facilitator) (BCL2L14), transcript variant 1 | |||||
![]() |
Human | > 80 % Preparation: Recombint protein was captured through anti-DDK affinity column followed by conventiol chromatography steps. Purity Detail: > 80% as determined by SDS-PAGE and Coomassie blue staining. |
HEK293 cells |
20 µg /
€438.00
|
|
OriGene Technologies, Inc. | |||||
TP315213 | Bcl-2-like 14 (transcript variant 4) |
||||
Recombinant protein of human BCL2-like 14 (apoptosis facilitator) (BCL2L14), transcript variant 4 | |||||
![]() |
Human | > 80 % Preparation: Recombint protein was captured through anti-DDK affinity column followed by conventiol chromatography steps. Purity Detail: > 80% as determined by SDS-PAGE and Coomassie blue staining. |
HEK293 cells |
20 µg /
€438.00
|
|
OriGene Technologies, Inc. | |||||
Lysates
Catalog No. | ||
---|---|---|
LY410728 | BCL2L14 overexpression lysate |
|
![]() |
0.1 mg /
€295.00
|
|
OriGene Technologies, Inc. | ||
LY429763 | BCL2L14 overexpression lysate |
|
![]() |
0.1 mg /
€295.00
|
|
OriGene Technologies, Inc. |
Human Lenti ORF Particles
Catalog No. | ||
---|---|---|
RC206404L2V | Lenti ORF particles, BCL2L14 (mGFP-tagged) - Human BCL2-like 14 (apoptosis facilitator) (BCL2L14), transcript variant 1, 200 uL, >10^7 TU/mL |
|
![]() |
200 µl /
€989.00
|
|
OriGene Technologies, Inc. | ||
RC216333L2V | Lenti ORF particles, BCL2L14 (mGFP-tagged) - Human BCL2-like 14 (apoptosis facilitator) (BCL2L14), transcript variant 3, 200 uL, >10^7 TU/mL |
|
![]() |
200 µl /
€989.00
|
|
OriGene Technologies, Inc. | ||
RC215213L2V | Lenti ORF particles, BCL2L14 (mGFP-tagged) - Human BCL2-like 14 (apoptosis facilitator) (BCL2L14), transcript variant 4, 200 uL, >10^7 TU/mL |
|
![]() |
200 µl /
€989.00
|
|
OriGene Technologies, Inc. | ||